Partner in Progress: Ferring Pharmaceuticals

BCAN is proud to partner with Ferring Pharmaceuticals in our shared quest to create better todays and more tomorrows for bladder cancer patients and families.

ADSTILADRIN® (nadofaragene firadenovec-vncg) was approved in the United States in 2022 and is fully available for appropriate patients as a treatment that may help people live better lives on their bladder cancer journey.

Click here to learn more about ADSTILADRIN.

A Bladder Cancer Patient: Fran’s Story

Fran’s Story:

Fran’s cancer journey began unexpectedly in her youth. At just 25 when most young adults are exploring life and building friendships, she faced a breast cancer diagnosis that shifted her focus from barhopping with friends to navigating chemotherapy and radiation treatments. After extensive treatment, Fran was fortunate to find herself in remission and began to build her life which included getting married to her now husband and starting a family.

Years later, having already battled breast cancer, she was devastated when diagnosed with high–risk non–muscle-invasive bladder cancer. When traditional BCG treatments failed, she found hope in ADSTILADRIN, an innovative therapy administered just once every three months. This treatment has allowed Fran to maintain her active lifestyle while fighting cancer, giving her the freedom to travel to faraway places, work in a career she loves, and enjoy life with her family and friends.

Now a volunteer with BCAN, Fran connects with newly diagnosed women, emphasizing the importance of regular checkups for early detection. Her story embodies both determination and optimism as she navigates her cancer journey on her own terms. With ADSTILADRIN, Fran has a renewed hope of keeping her bladder and remaining cancer-free, inspiring others with her message that even amid serious health challenges, it is possible to continue “doing it my way.”

Today, Fran’s story serves as a testament to the potential of innovative therapies, like ADSTILADRIN, to transform lives and redefine what is possible in uro-oncology care. Although this is Fran’s story, individual results may vary.

Fran’s podcast

Bladder cancer survivor Fran Curtis shares her powerful journey on Bladder Cancer Matters, discussing her experience with ADSTILADRIN®, the impact of early detection, and her advocacy work with BCAN.

More about ADSTILADRIN

ADSTILADRIN is a localized gene therapy designed to help the immune system fight NMIBC directly within the bladder. Administered once every 3 months, it works as a monotherapy, meaning it does not require combination with other medications to be effective. ADSTILADRIN is not chemotherapy or Bacillus Calmette-Guérin (BCG) treatment and does not require coadministration with BCG. It is an intravesical treatment option that may help preserve the bladder when BCG fails. It targets the cancer within the bladder without impacting the entire body, potentially reducing side effects. Importantly, it does not alter your genes; instead, it works with your immune system to stop the growth of cancer cells and destroy them. ADSTILADRIN is also designed for convenience, as it can be administered by your urologist in their office, allowing you to continue treatment with your current doctor.

For ADSTILADRIN patients, Ferring offers an excellent support mechanism in the Ferring Patient Assistance Program, which can even help determine how to navigate the financial aspects of bladder cancer treatment and survivorship. This program also offers patient assistance, coverage support, and other valuable resources for eligible uninsured/underinsured patients, including referrals to third-party organizations including 501(c)(3) charities, patient support and education groups, and state health exchange resources. Additionally, it offers help with scheduling appointments and staying on top of your treatment journey. It is as simple as enrolling, getting support, and staying supported.

STIL effective out to 5 years

At 3 months: More than half of the people who received instillations of ADSTILADRIN had a complete response (with no signs of high-grade bladder cancer) after just 1 dose (n=50)

At 1 year: 73% of people were estimated to keep their bladder

Out to 5 years: Of the people who received at least 1 dose of ADSTILADRIN, nearly half were estimated to keep their bladder and 96% of people did not progress to muscle invasive bladder cancer, even if their cancer didn’t go away completely (based on results from a transurethral resection of bladder tumors; n=103/107)

ADSTILADRIN upholds the commitment to helping people with bladder cancer live better lives by bringing science to life. This holds true for people like Fran, an actual ADSTILADRIN patient. Before ADSTILADRIN, Fran was already on her own bladder cancer journey, but her story does not start there.

Learn more about ADSTILADRIN and Ferring Uro-Oncology’s commitment to those with bladder cancer at adstiladrin.com and ferringusa.com.

Please click for Important Safety Information and full Prescribing Information.

INDICATION

ADSTILADRIN is a treatment for adults who have all the following:

• High-risk non–muscle-invasive bladder cancer (NMIBC)
• Cancer that is not responding to Bacillus Calmette-Guérin (BCG) therapy
• Carcinoma in situ (CIS) with or without other high-grade tumors

Ferring Access Support—Patient Assistance Program (PAP)

Ferring’s Patient Assistance Program offers patient assistance, coverage support, and other valuable resources for eligible uninsured/underinsured patients, including:

• Referrals to third-party organizations including 501(c)(3) charities, patient support and education groups, and state health exchange resources
• Help with scheduling appointments and staying on top of treatment

Clinical Trials

Listed below are bladder cancer clinical trials sponsored by Ferring. Click to read more about the trials, including summaries, eligibility and trial locations.

• Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
• Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

IMPORTANT SAFETY INFORMATION

Who should not receive ADSTILADRIN? Do not receive ADSTILADRIN if you have a sensitivity to interferon alfa or any of its components.

What is the most important information I should know about ADSTILADRIN? Individuals who are immunosuppressed or immune-deficient should not prepare, administer, receive, or come into contact with ADSTILADRIN.

What should I tell my healthcare provider? Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of ADSTILADRIN? The most common side effects of ADSTILADRIN include: Urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in your urine.

These are not all the possible side effects of ADSTILADRIN. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING.

What other information should I know about using ADSTILADRIN? For 2 days following treatment, voided urine should be disinfected for 15 minutes with an equal volume of bleach before flushing.

For more important information, call 1-888-337-7464.

Please see full Prescribing Information.